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Surgery remains the only potential cure for pancreatic 
cancer, and many lesions can nowadays be detected 
while premalignant allowing prophylactic surgery to 
take place. As always with any medical care, harms 
and benefits of the treatment need to be balanced. This 
is especially challenging in case of pancreatic surgery, 
which has notoriously been prone to complications, 
pancreatic fistula being the most fearsome. Several 
attempts to reduce the rate of pancreatic fistula have 
been made in the past, and tens, if not hundreds, of 
different anastomosis and stump closure techniques 
have been introduced with more or less similar results 
than the previous ones. Furthermore, trials using peri-
operative medical therapy to reduce pancreatic fluid 
output using octreotide (a somatostatin analogue) 
have not been able to demonstrate clear benefit in 
terms of reducing clinically significant fistulas. As a 
result, postoperative pancreatic fistula remains a com-
mon problem worldwide. The phrase “Eat when you 
can, sleep when you can, and don’t mess with the pan-
creas” is well known for any surgical resident. Luckily, 
pancreatic surgery is becoming more safe.
Several advances in reducing pancreatic fistula rate 
have been reported recently. Perioperative pasireotide 
was shown to halve severe pancreatic complications 
compared to placebo (9.2% vs 20.9%) (1). Pasireotide is 
also a somatostatin analogue, but targets more sub-
types of somatostatin receptors with higher affinity 
compared to octreotide, possibly explaining the bene-
fit. Perioperative hydrocortisone therapy was demon-
strated to have similar trend in reducing clinically 
significant pancreatic fistula rate (11% vs 27%) (2), but 
the mechanism by which hydrocortisone reduces 
these complications remains unclear. On the technical 
side, DISCOVER trial showed that reinforcing the dis-
tal pancreatectomy suture/staple line using teres liga-
ment patch reduced reoperation rates (1.3% vs 13.0%) 
(3). While perioperative medication and techniques 
matter, anesthesiologists should also take note. 
Recently published HYSLAR trial compared restric-
tive fluid regimen of 3% hypertonic saline with lac-
tated Ringer’s solution and showed a 25% reduction 
in complications after adjustments for age, weight, 
and pancreatic texture (4).
In this issue of Scandinavian Journal of Surgery, Jiang 
et al. (5) present another approach for reducing pan-
creatic fistula rates—an active drainage compared to 
traditionally used passive drainage method. This 
method included a double-lumen drain, which con-
tinuously irrigated and sucked the drainage site. 
While there were no differences regarding total pan-
creatic fistula rate, the most severe (grade 3) fistulas 
were reduced by this active drainage compared to 




traditional passive drainage (0% vs 6.4%). Thus, it 
seems that this method provides a possibility to con-
vert severe fistulas into less severe ones.
Who is then in need of a drainage after pancreati-
coduodenectomy? Two recent multicenter trials have 
been addressing this question (6, 7). Both found that 
routine drainage is not necessary, and drains can be 
safely omitted in patients with low risk of fistula. 
Recently proposed Fistula Risk Score is one possibility 
to classify patients based on their risk for fistula (8).
Pancreatic surgery is undergoing a revolution. 
Boundaries for indications of radical resection are con-
tinuously being pushed and vascular resections with 
reconstruction are becoming a standard of care. Safety 
of the procedures is improving not only due to inno-
vative new methods discussed above but also due to 
increase in centralization of pancreatic surgery (9). 
Small, but significant, improvements in long-term 
survival are also being recognized, and up to 44% 
5-year survival rates have been reported for pancre-
atic ductal adenocarcinoma in recent oncological 
trials (10).
Still a lot of work needs to be done. How radical 
vascular resections are indicated? Should neoadju-
vant therapy be given, and to which patients? What 
is the most efficient adjuvant therapy? What is the 
optimal fistula preventing medical perioperative 
therapy? Which patients would be better off without 
drains, and which patients should have an active 
drainage? We are eagerly waiting for further trials 
and research to improve pancreatic surgery even 
further.
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